<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04687800</url>
  </required_header>
  <id_info>
    <org_study_id>The McTENZA Study</org_study_id>
    <nct_id>NCT04687800</nct_id>
  </id_info>
  <brief_title>Clinical Investigation of the Dextenza 0.4mg Intracanalicular Insert Delivery System Used in Cataract Surgery</brief_title>
  <official_title>A Randomized, Clinical Investigation of the Dextenza 0.4mg Intracanalicular Insert Delivery System Used in Conjunction With Cataract Surgery Performed in Combination With Minimally Invasive Glaucoma Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cathleen McCabe MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ocular Therapeutix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Eye Associates</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To monitor intraocular pressure in glaucoma patients after cataract surgery preformed in&#xD;
      conjunction with minimally invasive glaucoma surgery (MIGS)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to monitor glaucoma patients intraocular pressure (IOP) after&#xD;
      cataract surgery performed in conjunction with minimally invasive glaucoma surgery. After&#xD;
      qualifying for this study, subjects will be randomized in a 1:1 allocation of one of two&#xD;
      arms. The purpose of this study is to determine if Dextenza (dexamethasone) 0.4mg&#xD;
      intracanalicular insert delivery system, provides a decreased risk of elevated post-operative&#xD;
      IOP vs. standard therapy controlled topical steroid Durezol (Difluprednate ophthalmic&#xD;
      emulsion) 0.05%&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 4, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label prospective randomized comparative investigator -initiated study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Intraocular Pressure from Baseline</measure>
    <time_frame>30 days - IOP measured at day 1, day 14 and day 30</time_frame>
    <description>Sustained tapered release of Dextenza compared to Durezol 4 week taper as measured by mean IOP from baseline.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Dextenza 0.4mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intracanalicular insert</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Durezol 0.05%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>difluprednate ophthalmic emulsion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextenza 0.4mg intracanalicular Insert</intervention_name>
    <description>intracanalicular insert delivery system</description>
    <arm_group_label>Dextenza 0.4mg</arm_group_label>
    <other_name>dexamethasone ophthalmic insert</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durezol 0.05% Ophthalmic Emulsion</intervention_name>
    <description>Standard therapy, topical steroid drop</description>
    <arm_group_label>Durezol 0.05%</arm_group_label>
    <other_name>difluprednate ophthalmic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 or Older&#xD;
&#xD;
          -  Mild-to-moderate primary open angle glaucoma and visually significant cataract with&#xD;
             plans to undergo clear cornea cataract surgery with Phacoemulsification and&#xD;
             implantation of posterior chamber IOL combined with minimally invasive glaucoma&#xD;
             surgery ( MIGS) procedure in both eyes.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of Topical steroid, systemic steroid or intravitreal steroid implants within last&#xD;
             3 months&#xD;
&#xD;
          -  Previous Corneal surgery or pathology&#xD;
&#xD;
          -  Active or history of chronic or recurrent inflammatory eye disease in either eye&#xD;
&#xD;
          -  Ocular Pain in either eye&#xD;
&#xD;
          -  Proliferative diabetic retinopathy in either eye&#xD;
&#xD;
          -  Significant macular pathology detected on macular optical coherence tomography&#xD;
             evaluation at the screening visit in either eye.&#xD;
&#xD;
          -  Laser or incisional ocular surgery during the study period and 6 months prior in&#xD;
             either eye&#xD;
&#xD;
          -  Systemic concomitant pain medication management with the pharmacology class of&#xD;
             Oxycodone&#xD;
&#xD;
          -  Systemic NSAIDS use &gt;/=750 mg daily&#xD;
&#xD;
          -  Clinically significant macular edema&#xD;
&#xD;
          -  History of cystoid macular edema in either eye&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cathleen M McCabe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Eye Associates of Manatee</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Khrystina Cozby, COA</last_name>
    <phone>9412205987</phone>
    <email>kcozby@theeyeassociates.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carole Kringel, COT</last_name>
    <phone>9412205987</phone>
    <email>ckringel@theeyeassociates.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Eye Associates of Manatee</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.theeyeassociates.com/</url>
    <description>Sponsor/ site website</description>
  </link>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 8, 2020</study_first_submitted>
  <study_first_submitted_qc>December 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2020</study_first_posted>
  <last_update_submitted>December 29, 2020</last_update_submitted>
  <last_update_submitted_qc>December 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Eye Associates</investigator_affiliation>
    <investigator_full_name>Cathleen McCabe MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Difluprednate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

